ArticleFrontiers in immunology2026
FAERS database reveals latent signals of neuro-ophthalmic toxicity associated with immune checkpoint inhibitors: feature mining and clinical warnings.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To perform signal mining of neuro-ophthalmic immune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICIs) using the FDA Adverse Event Reporting System (FAERS), and to synthesize their clinical manifestations and temporal patterns, thereby providing evidence-based insights for optimizing clinical drug safety. Methods: Reports of neuro-ophthalmic irAEs associated with ICIs were extracted from the FAERS (Q1 2011 to Q4 2025). Signal detection was performed using disproportionality analysis methodologies, specifically the Reporting Odds Ratio (ROR) and Information Component (IC) algorithms, with predefined statistical thresholds for signal significance. Results: A total of 521 reports identified neuro-ophthalmic irAEs with ICIs as primary suspect drugs, predominantly affecting males and elderly patients At the High-Level Group Term (HLGT) level, positive signals were detected for pembrolizumab and avelumab. Preferred Term (PT) analysis revealed six significant signals, with eyelid ptosis being the most frequently reported event. The median time to onset was 28-38 days, with acute presentations (≤24 hours post-infusion) observed for pembrolizumab and nivolumab; both agents exhibited elevated case fatality proportions, with a higher proportion of male patients among fatal cases. Conclusion: This study delineated potential neuro-ophthalmic positive disproportionality signals across seven ICIs, revealing demographic variations in signal reporting frequency with higher susceptibility among males and elderly patients. Pembrolizumab and avelumab were associated with higher reporting frequencies of neuro-ophthalmic adverse events, which were related to poor visual outcomes. Consequently, prompt recognition and management of neuro-ophthalmic irAEs are imperative to enhance ICI safety profiles in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.